Related references
Note: Only part of the references are listed.Meningococcal Vaccines: Current Issues and Future Strategies
Amanda C. Cohn et al.
DRUGS (2013)
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
Timo Vesikari et al.
LANCET (2013)
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
Ulrich Vogel et al.
LANCET INFECTIOUS DISEASES (2013)
Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules A Randomized Controlled Trial
Nicoletta Gossger et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study
Maria Elena Santolaya et al.
LANCET (2012)
Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197 Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates
Alan Kimura et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Multicenter, Open-Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy
Jamie Findlow et al.
CLINICAL INFECTIOUS DISEASES (2010)
Review of Meningococcal Group B Vaccines
Dan M. Granoff
CLINICAL INFECTIOUS DISEASES (2010)
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines
John Donnelly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Characterization of fHbp, nhba (gna2132), nadA, porA, Sequence Type (ST), and Genomic Presence of IS1301 in Group B Meningococcal ST269 Clonal Complex Isolates from England and Wales
Jay Lucidarme et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Meningococcal carriage and disease-Population biology and evolution
Dominique A. Caugant et al.
VACCINE (2009)
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
David S. Stephens et al.
LANCET (2007)
Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines
Caroline L. Trotter et al.
FEMS MICROBIOLOGY REVIEWS (2007)
Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit
Stephen J. Gray et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2006)
Vaccine potential of the Neisseria meningitidis 2086 lipoprotein
LD Fletcher et al.
INFECTION AND IMMUNITY (2004)
Medical progress: Meningococcal disease.
NE Rosenstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing
M Pizza et al.
SCIENCE (2000)
Share Paper
